How Much Does Prostate Artery Embolisation Cost?

Prostate artery embolisation (PAE) typically costs between roughly $1,700 and $3,900 in direct procedural expenses, depending on the facility type and what the cost analysis includes. That range comes from published cost studies, not patient bills, so your actual out-of-pocket figure will depend on insurance coverage, geographic location, and whether the procedure is done in a hospital or an outpatient lab. What the research consistently shows, though, is that PAE costs substantially less than the surgical alternative it is most often compared against, transurethral resection of the prostate (TURP), largely because PAE patients go home the same day.

What the Procedure Itself Costs

A 2024 cost-comparison study broke down PAE expenses item by item across two settings: a hospital interventional radiology suite and a freestanding outpatient-based lab (OBL). The total came to about $3,858 in the hospital and $3,643 in the outpatient lab.¹ The difference is modest, and the cost drivers are similar in both settings. Personnel accounts for the largest share, eating up about 53 to 55 percent of the total in either case. That includes the interventional radiologist performing the procedure, nursing staff, and radiology technologists. Equipment costs were slightly higher in the hospital setting, while space-related overhead was slightly higher in the outpatient lab, but neither gap was large enough to meaningfully change the bottom line.

Material costs, which cover catheters, embolic microspheres, contrast dye, and other disposables, were essentially the same regardless of where the procedure took place.¹ The takeaway for patients is that choosing a hospital over an outpatient lab is unlikely to save you money on the procedure itself. Other factors, like how the facility negotiates with your insurer or what it charges for the room and recovery time, matter more than the raw cost of doing the embolisation.

How PAE Compares to TURP

The cost gap between PAE and TURP is where the numbers get striking. A direct comparison of in-hospital expenses found that total costs for TURP averaged about $5,338, compared to roughly $1,678 for PAE.² The biggest reason for the difference is not the procedure itself. Intra-procedural supplies for PAE were actually more expensive than for TURP (about $1,473 versus $1,081), because PAE requires specialty microcatheters and embolic agents. But TURP needs general or spinal anaesthesia, an operating room team, and a longer hospital stay, which drives the total cost well beyond what PAE requires.

The average length of stay tells the story most clearly. PAE patients in that study stayed an average of about three hours (0.125 days), while TURP patients stayed an average of 1.38 days.² An overnight hospital stay adds nursing shifts, bed charges, meals, and post-operative monitoring, all of which accumulate quickly. PAE is performed under local anaesthesia with conscious sedation, which eliminates the anaesthesia team’s fees and the recovery room time that follows general anaesthesia. When you strip out the hospitalisation overhead, PAE’s cost advantage shrinks, but the hospitalisation overhead is a real part of what patients and insurers pay.

A US-based cost-effectiveness analysis found a similar pattern, putting PAE procedure costs at about $2,934 and TURP at roughly $6,038.³ Studies from outside the US echo the same direction. A UK analysis reported PAE at £2,000 versus TURP at £3,028.⁴ A European study found PAE cost €2,905 versus €3,847 for TURP at the one-year mark.⁵ The absolute numbers vary across healthcare systems, but the direction is remarkably consistent: PAE costs somewhere between 33 and 68 percent of what TURP costs, depending on the study and the country.

Cost-Effectiveness Over the Longer Term

A common concern with PAE is that its symptom relief might not last as long as surgery, which could lead to retreatment and push the total long-term expense higher. The cost-effectiveness studies address this directly, and the picture is more reassuring than you might expect.

The US cost-effectiveness analysis found that over a multi-year horizon, PAE and TURP delivered nearly identical quality-adjusted outcomes (about 2.845 versus 2.854 quality-adjusted life years), while PAE maintained a cost advantage of roughly $3,100.³ That analysis accounted for the possibility of retreatment and still found PAE to be the more cost-effective strategy, even under extreme assumptions about recurrence rates, adverse events, and costs.

The European study pushed the timeline out to five years and found the gap narrowed but did not disappear. PAE cost about €4,117 per patient over five years, compared to €4,298 for TURP.⁵ The quality-of-life outcomes at five years slightly favoured PAE (4.572 versus 4.487 quality-adjusted life years), a finding that ran in the opposite direction from the UK one-year study, which found TURP slightly better in quality-of-life terms.⁴ The UK analysis nonetheless concluded PAE was cost-effective, because the cost savings were large enough to justify the small quality-of-life trade-off under the UK’s national threshold for healthcare value.

The practical implication is that even if a fraction of PAE patients eventually need a second procedure or a surgical follow-up, the upfront savings are large enough that PAE remains a financially sensible choice for most patients. The retreatment question matters more for clinical decision-making than for financial planning.

What Insurance Typically Covers

PAE has a recognised CPT code (37243), which means it can be billed to insurance as a distinct procedure. In the United States, Medicare and most private insurers do cover PAE when it is deemed medically necessary for benign prostatic hyperplasia (BPH) that has not responded to medication. However, “medically necessary” criteria vary by plan, and some insurers still treat PAE as investigational or require prior authorisation, which can delay or complicate coverage.

If your insurer covers the procedure, your out-of-pocket cost will depend on your plan’s deductible, co-insurance rate, and whether the facility is in-network. For a procedure with a total cost in the range described above, patients with typical commercial insurance might expect to pay anywhere from a few hundred dollars to a couple of thousand, depending on where they are in their annual deductible. Patients on Medicare generally face lower out-of-pocket expenses because Medicare tends to cover a higher share of outpatient procedures.

For self-pay patients, the picture is murkier. Published cost analyses report the direct cost of delivering the procedure, not the price a facility charges. Facility charges, what actually appears on your bill before insurance adjustments, are typically higher than the underlying cost because they include institutional overhead and margin. If you are paying out of pocket, it is worth asking the facility for a cash-pay or self-pay price, which is often negotiable and can be substantially lower than the listed charge.

Hidden Costs That Do Not Show Up in Published Studies

The cost figures cited above capture the procedure itself and the immediate hospital or lab fees, but they generally do not include several expenses that affect what you actually spend.

Pre-procedure workup: Most patients undergo a prostate MRI or CT angiography before PAE to map the prostatic arteries and confirm anatomy suitable for embolisation. An MRI can run $500 to $3,000 depending on your insurance and location. You will also typically need a urological consultation, blood tests (including a PSA level), and sometimes a cystoscopy or urodynamic study if symptoms are ambiguous.
Follow-up imaging: Some centres perform a follow-up MRI at three to six months to assess prostate volume reduction. This is not universal, but if your provider orders it, it adds another imaging cost.
Medication costs: Many patients continue taking BPH medications for a few weeks after PAE while waiting for the prostate to shrink. If you were already on these medications, this is not a new expense, but it is worth knowing that PAE does not eliminate pharmacy costs overnight.
Lost income: PAE recovery is faster than TURP, and most patients return to normal activity within a few days. But you will still likely miss one to three days of work, which carries a real cost even if it does not appear on a medical bill.

Published cost analyses tend to focus on direct procedural expenses because those are what hospitals and health systems control. From the patient’s perspective, the total financial commitment is broader, and the pre-procedure imaging is often the most significant add-on.

How Operator Experience Affects Resources

PAE is a technically demanding procedure that involves navigating tiny catheters through a complex network of pelvic arteries. There is a well-documented learning curve, and it has indirect financial implications. A study of 296 PAE procedures found that operators showed significant improvements in procedure time, fluoroscopy time, and contrast volume used as they gained experience. The inflection points came at roughly 73 to 78 procedures, meaning that a physician who has performed fewer than about 75 PAEs is still on the steeper part of the learning curve.⁶

Why does this matter for cost? Longer procedure times mean more staff hours and more facility time, both of which drive up the bill. More contrast dye used means higher material costs. More fluoroscopy time means greater radiation exposure, which does not directly cost you money but does reflect procedural efficiency. While the cost studies do not explicitly model the learning-curve effect on price, it is reasonable to expect that a centre performing PAE regularly will be faster, use fewer resources per case, and potentially pass some of that efficiency on through lower charges. When choosing a provider, asking about case volume is not just a quality question. It is a cost question.

Why Published Cost Figures Vary So Much

If you have been researching PAE costs online, you have probably noticed that quoted figures range from under $2,000 to over $15,000. Part of the confusion comes from mixing up different types of numbers. Published cost analyses, like the ones described above, estimate the actual economic cost of delivering the procedure: staff time, supplies, equipment, and space. These tend to land in the $1,700 to $3,900 range for PAE. Facility charges, which are the sticker prices hospitals set before insurance negotiation, are typically much higher. And what you pay out of pocket is a third number entirely, determined by your insurance contract.

Geography matters as well. Healthcare prices in the United States vary dramatically by region, with procedures in major metropolitan areas often costing two to three times what the same procedure costs in smaller markets. The published cost studies come from specific institutions, so their numbers reflect those institutions’ cost structures. A PAE performed at a large academic medical centre in New York will almost certainly carry higher charges than the same procedure at a community interventional radiology practice in the Midwest, even though the clinical inputs are essentially the same.

Currency differences add another layer. The UK study reporting PAE at £2,000 and the European study reporting it at about €2,900 are not directly comparable to US dollar figures, because healthcare cost structures, staff salaries, and supply chain pricing differ across countries. What is comparable is the relative cost advantage over TURP, which holds across all the healthcare systems studied.

When PAE Might Not Be the Cheaper Option

There are scenarios where PAE’s cost advantage shrinks or disappears. If the procedure fails to provide adequate symptom relief and you end up needing TURP (or another surgical intervention) afterward, you have effectively paid for two procedures. Retreatment rates after PAE vary across studies, but they are higher than after TURP, particularly beyond the three-to-five-year mark. The cost-effectiveness analyses account for this by modelling retreatment probability into their calculations and still find PAE favourable on balance, but for an individual patient who does need retreatment, the financial picture is less rosy.

Patients with very large prostates, unusual vascular anatomy, or significant atherosclerotic disease in the pelvic arteries may face longer, more complex procedures that consume more supplies and staff time. In some cases, the anatomy may not permit complete embolisation, leading to a suboptimal result that requires a second attempt or a surgical fallback. These situations are not common, but they represent a real tail risk that the average cost figures do not capture.

There is also the question of whether PAE is compared against TURP specifically or against newer surgical alternatives like laser enucleation or aquablation. TURP is the traditional benchmark and tends to be on the more expensive end of surgical options. Some newer procedures have shorter hospital stays and may narrow the cost gap with PAE, though head-to-head economic comparisons with these newer techniques are still limited.

Comparing Costs Across Countries

The research base on PAE costs is genuinely international, which is useful for patients outside the US who are trying to gauge what to expect. In the UK, PAE procedure costs were reported at about £2,000 in a study that compared it directly against TURP at £3,028.⁴ PAE is available through the NHS at some centres, though access varies by region, and waiting times can be long. Privately, UK patients may pay £5,000 to £8,000 for the procedure including consultation and imaging, reflecting the markup between cost-to-deliver and price-to-patient that exists in every healthcare system.

In continental Europe, the five-year cost analysis put PAE at about €4,117 per patient, including follow-up and any retreatment costs, versus €4,298 for TURP.⁵ The convergence at five years is worth noting: while PAE is clearly cheaper upfront, the long-term cost difference is modest once you factor in follow-up care and the possibility of retreatment. For patients in countries with universal healthcare, the financial impact is mostly felt in waiting times and the choice between public and private treatment rather than in direct out-of-pocket expenses.

Medical tourism for PAE does exist, particularly to centres in Portugal, which has one of the world’s most experienced PAE programmes. Patients travelling internationally should factor in travel, accommodation, follow-up logistics, and the difficulty of managing any complications remotely. The procedure cost savings may be real, but the total expense of travelling for healthcare is easy to underestimate.

What to Ask Your Provider

If you are considering PAE and want to understand your personal cost exposure, there are specific questions worth raising early in the process. Ask whether the quoted price includes the pre-procedure imaging or whether that is billed separately. Ask how many PAE procedures the operator has performed; centres beyond the learning curve inflection point are likely to be more efficient and may have better-negotiated supply costs.⁶ Ask whether the procedure will be done in a hospital suite or an outpatient lab, not because the cost difference is dramatic, but because outpatient labs sometimes have more transparent pricing and lower facility fees.

If you are uninsured or underinsured, ask explicitly about a self-pay rate. Many interventional radiology practices offer bundled pricing for cash-pay patients that includes the procedure, sedation, and same-day recovery. These bundles can be significantly lower than the sum of individually billed components. And if your insurer initially denies coverage, ask your provider’s office about the appeals process. PAE has a growing evidence base supporting its effectiveness, and denials based on “investigational” status are increasingly being overturned on appeal as professional society guidelines catch up with the data.